DOP2014000030A - Procedimientos para la fabricación de medicamentos útiles para el tratamiento de infecciones virales - Google Patents

Procedimientos para la fabricación de medicamentos útiles para el tratamiento de infecciones virales

Info

Publication number
DOP2014000030A
DOP2014000030A DO2014000030A DO2014000030A DOP2014000030A DO P2014000030 A DOP2014000030 A DO P2014000030A DO 2014000030 A DO2014000030 A DO 2014000030A DO 2014000030 A DO2014000030 A DO 2014000030A DO P2014000030 A DOP2014000030 A DO P2014000030A
Authority
DO
Dominican Republic
Prior art keywords
manufacture
treatment
procedures
viral infections
useful drugs
Prior art date
Application number
DO2014000030A
Other languages
English (en)
Inventor
Jill Walker
Christian Voitenleitner
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47715500&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DOP2014000030(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of DOP2014000030A publication Critical patent/DOP2014000030A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención proporciona un procedimiento para la fabricación de medicamentos útiles para el tratamiento de Hepatitis C en un ser humano que lo necesite, el cual comprende un compuesto de las fórmulas (II) o (IIB) descrito en la presente, o una sal farmacéuticamente aceptable del mismo, en combinación con uno o más agentes terapéuticos alternativos para Hepatitis C.
DO2014000030A 2011-08-17 2014-02-17 Procedimientos para la fabricación de medicamentos útiles para el tratamiento de infecciones virales DOP2014000030A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161524429P 2011-08-17 2011-08-17
US201161526787P 2011-08-24 2011-08-24

Publications (1)

Publication Number Publication Date
DOP2014000030A true DOP2014000030A (es) 2014-06-30

Family

ID=47715500

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2014000030A DOP2014000030A (es) 2011-08-17 2014-02-17 Procedimientos para la fabricación de medicamentos útiles para el tratamiento de infecciones virales

Country Status (22)

Country Link
US (2) US9119868B2 (es)
EP (1) EP2744342B1 (es)
JP (2) JP6121419B2 (es)
KR (2) KR20140093209A (es)
CN (2) CN103929965B (es)
AU (1) AU2012296446B2 (es)
BR (1) BR112014003556A2 (es)
CA (1) CA2843502C (es)
CL (2) CL2014000394A1 (es)
CO (1) CO6880064A2 (es)
CR (1) CR20140075A (es)
DO (1) DOP2014000030A (es)
EA (2) EA201690327A1 (es)
ES (1) ES2735542T3 (es)
IL (1) IL230484A (es)
MA (1) MA35347B1 (es)
MX (1) MX2014001833A (es)
PE (1) PE20141391A1 (es)
PH (1) PH12014500381A1 (es)
SG (1) SG10201606646RA (es)
WO (1) WO2013025992A1 (es)
ZA (2) ZA201400435B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014003556A2 (pt) * 2011-08-17 2017-03-21 Glaxosmithkline Llc método de tratamento de vírus, e, composição farmacêutica
PT2744332T (pt) * 2011-08-19 2017-01-24 Glaxo Group Ltd Compostos de benzofurano para o tratamento de infeções por vírus de hepatite c
US20170312297A1 (en) * 2014-11-10 2017-11-02 Glaxosmithkline Intellectual Property (No. 2) Limited Long Acting Pharmaceutical Compositions For Hepatitis C
PE20170922A1 (es) * 2014-11-10 2017-07-12 Glaxosmithkline Intellectual Property (No 2) Ltd Composiciones de accion prolongada de combinacion y procedimientos para hepatitis c
CN105732602B (zh) * 2015-09-23 2017-04-19 常州寅盛药业有限公司 作为ns4b抑制剂的苯并呋喃类似物
JP7086987B2 (ja) * 2017-03-21 2022-06-20 ザ スクリプス リサーチ インスティテュート 銅およびニッケル触媒による脱炭酸ホウ素化反応
EP4049680A4 (en) * 2019-10-25 2024-01-10 Sumitomo Pharma Co., Ltd. NEW SUBSTITUTED CONDENSED RING CONNECTION

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001002424A2 (en) * 1999-07-07 2001-01-11 Du Pont Pharmaceuticals Company Peptide boronic acid inhibitors of hepatitis c virus protease
CN1731993A (zh) * 2002-11-01 2006-02-08 维洛药品公司 苯并呋喃化合物、组合物以及治疗和预防丙型肝炎病毒感染及相关疾病的方法
WO2005051318A2 (en) 2003-11-24 2005-06-09 Viropharma Incorporated Compounds, compositions and methods for treatment and prophylaxis of hepatitis c viral infections and associated diseases
CA2651212A1 (en) * 2006-05-02 2007-11-15 Anacor Pharmaceuticals, Inc. Hydrolytically-resistant boron-containing therapeutics and methods of use
WO2009023179A2 (en) 2007-08-10 2009-02-19 Genelabs Technologies, Inc. Nitrogen containing bicyclic chemical entities for treating viral infections
GB0719366D0 (en) * 2007-10-03 2007-11-14 Smithkline Beecham Corp Compounds
EP2245023B1 (en) * 2008-02-14 2011-12-28 F. Hoffmann-La Roche AG Heterocyclic antiviral compounds
WO2009137500A1 (en) * 2008-05-05 2009-11-12 Wyeth 6-substituted benzofuran compounds to treat infection with hepatitis c virus
WO2011050284A1 (en) * 2009-10-23 2011-04-28 Glaxosmithkline Llc Pyrazolylpyridine antiviral agents
AR080185A1 (es) 2010-02-19 2012-03-21 Glaxo Group Ltd Derivados de acido boronico y benzofurano, composiciones farmaceuticas que los contienen,y uso de los mismos en el tratamiento y/o prevencion de infecciones virales, en particular por el virus de hepatitis c(hcv).
AU2011329485A1 (en) * 2010-11-18 2013-04-18 Glaxo Group Limited Compounds
BR112014003556A2 (pt) * 2011-08-17 2017-03-21 Glaxosmithkline Llc método de tratamento de vírus, e, composição farmacêutica
WO2013025975A1 (en) * 2011-08-17 2013-02-21 Glaxosmithkline Llc Combination treatments for hepatitis c
PT2744332T (pt) * 2011-08-19 2017-01-24 Glaxo Group Ltd Compostos de benzofurano para o tratamento de infeções por vírus de hepatite c
PH12014500386A1 (en) * 2011-08-24 2019-10-07 Glaxosmithkline Llc Combination treatment for hepatitis c

Also Published As

Publication number Publication date
IL230484A (en) 2016-11-30
MA35347B1 (fr) 2014-08-01
ES2735542T3 (es) 2019-12-19
US9119868B2 (en) 2015-09-01
KR101975233B1 (ko) 2019-05-07
JP2014524446A (ja) 2014-09-22
ZA201400435B (en) 2015-09-30
KR20180129973A (ko) 2018-12-05
IL230484A0 (en) 2014-03-31
CN103929965A (zh) 2014-07-16
PH12014500381A1 (en) 2021-07-12
EA201690327A1 (ru) 2016-06-30
EA024357B1 (ru) 2016-09-30
SG10201606646RA (en) 2016-09-29
CN106109479A (zh) 2016-11-16
CA2843502A1 (en) 2013-02-21
EP2744342A1 (en) 2014-06-25
KR20140093209A (ko) 2014-07-25
NZ619985A (en) 2016-06-24
EP2744342A4 (en) 2015-01-28
EP2744342B1 (en) 2019-04-24
ZA201502595B (en) 2017-01-25
CO6880064A2 (es) 2014-02-28
MX2014001833A (es) 2014-02-27
EA201490199A1 (ru) 2015-01-30
JP2017165732A (ja) 2017-09-21
CR20140075A (es) 2014-03-24
EA201490199A8 (ru) 2015-12-30
CA2843502C (en) 2019-01-15
US10238678B2 (en) 2019-03-26
US20150320777A1 (en) 2015-11-12
BR112014003556A2 (pt) 2017-03-21
CL2016000300A1 (es) 2016-09-02
AU2012296446A1 (en) 2014-02-13
CN103929965B (zh) 2016-08-17
US20140212384A1 (en) 2014-07-31
PE20141391A1 (es) 2014-10-29
AU2012296446B2 (en) 2015-07-09
WO2013025992A1 (en) 2013-02-21
CL2014000394A1 (es) 2014-08-01
JP6121419B2 (ja) 2017-04-26

Similar Documents

Publication Publication Date Title
CR20140086A (es) Tratamientos de combinación para hepatitis c
DOP2021000147A (es) Combinacion terapeutica que comprende lamivudina
SV2015005115A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
MX2019001575A (es) Agentes terapeuticos para enfermedades neurodegenerativas.
DOP2014000030A (es) Procedimientos para la fabricación de medicamentos útiles para el tratamiento de infecciones virales
MX2017003819A (es) Macrociclos peptidomimeticos y formulaciones de los mismos.
ECSP109889A (es) Composiciones terapeuticas y usos de las mismas
ECSP18069924A (es) Compuestos tetracíclicos de piridona como antivirales
ECSP109897A (es) Composiciones terapeuticas y usos de las mismas
GT201500030A (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
CR20130043A (es) Compuestos terapéuticos
CL2013001428A1 (es) Compuesto que inhibe la actividad del virus de la hepatitis c (hcv); composición farmacéutica que comprende el compuesto; método de tratamiento de hepatitis c.
MX2020007023A (es) Analogos detiadiazol y metodos para el tratamiento de afecciones relacionadas con la deficiencia del gen de supervivencia de las neuronas motoras (smn).
AR101740A1 (es) Terapia de combinación y composiciones
MX2014003180A (es) Metodos para tratar vhc.
MX2020012924A (es) Terapias combinadas de coenzima q10 para el tratamiento de cancer.
GT201600269A (es) Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble
MX368903B (es) Compuestos terapéuticos y sus usos en el tratamiento de enfermedades proliferativas.
UY35211A (es) Compuestos tricíclicos
MX2017003780A (es) Composicion farmaceutica para tratar colitis ulcerativa.
ECSP13012551A (es) Terapia de combinación para tratar infección por hcv.
UY36124A (es) Derivados de carboxamida
PE20180928A1 (es) Sales y profarmacos de 1-metil-d-triptofano
UY35209A (es) Compuestos tricíclicos
BR112014008783A2 (pt) compostos para o tratamento e profilaxia da doença causada por vírus sincicial respiratório